Company:  ATARA BIOTHERAPEUTICS, IN ... (ATRA)
Form Type:  8-K
Filing Date:  1/4/2018 
CIK:  0001604464 
Address:  611 GATEWAY BLVD
SUITE 900
 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  650-278-8930 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$39.20  
Change: 
-0.10 (-0.25%)  
Trade Time: 
Jul 20  
Market Cap: 
$1.72B
Trade ATRA now with 

© 2018  
Description of Business
Atara Biotherapeutics is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. Atara's most advanced T-cell immunotherapy in development, tabelecleucel (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus, or EBV, associated post-transplant lymphoproliferative disorder, or EBV+ PTLD, who have failed rituximab, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma, or NPC.
Register and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      Item 8.01. Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 1.1
    Issuer Free Writing Prospectus dated January 3, 2018
  EXHIBIT 5.1
  EXHIBIT 99.1